摘要
目的比较分析腔内等离子汽化切割系统行治疗良性前列腺增生(Benign prostatic hyperplasia,BPH)的两种术式:经尿道等离子前列腺电切术(Transurethral plasmakinetic resction of prostate,TUPKP)与经尿道等离子汽化剜切术(Tansurethral vpor Enucleation rsection of the prostate,TVERP)的临床疗效。方法回顾性分析2009年10月至2014年11月在某院行TUPKP和TVERP治疗的良性前列腺增生的病例资料,其中TUPKP组70例,TVERP组46例。通过手术操作用时、术中失血量、切除腺体体积、术后膀胱持续冲洗时间和并发症机率评价两种手术方式围手术期安全性;通过比较术后3个月前列腺症状主观及客观评分表、尿流动力学指标评价两种手术方式的疗效。结果两组数据比较TVERP治疗组术中出血量、术后膀胱冲洗时间相对低、前列腺切除重量相对高、并发症机率低(P<0.05);术后3个月两组最大尿流率(Qmax)、残尿量(PRV)、国际前列腺症状评分(IPSS)、生活质量评分(QOL)较术前均明显改善,但两组间比较差异无显著性(P>0.05)。结论经尿道等离子汽化剜切术治疗前列腺增生手术安全性更好,短期疗效与等离子前列腺电切术相当,是一种治疗良性前列腺增生相对理想的手术方法。
Objective To report the comparison of the clinical effects for benign prostatic hyperplasia between transurethral plasmakinetic resction of prostate and transurethral vapor enucleation resection of the prostate.Methods A total of 116 patients with BPH were enrolled from October 2009 to Novermber 2014 and divided into TVERP group （46 cases） and TUPKP group（70cases）.Parameters including intraoperative blood loss, resected tissue weight, operating time, postoperative washing time of bladder and postoperative morbidity rate were compared to evaluate the clinical safety of TVERP and TUPKP for the treatment of BPH.Results TVERP has lower intraoperative blood loss, complication and postoperative washing time of bladder, and has higher resected tissue weight（P〈0.05）. International prostate symptom scores（IPSS）,quality of life scores（QOL）,maximum urinary flow rates（Qmax） and postvoid residual volumes（PRV）of postoperation were significantly improved compared to 3 months preoperative. But there was no significant difference between two groups（P〉0.05）.Conclusion TVERP has higher security in the treatment of BPH.Both of them have similar efficacy in the treatment of BPH.TVERP is a relatively ideal treatment of benign prostatic hyperplasia.
出处
《中国病案》
2015年第6期94-96,共3页
Chinese Medical Record
关键词
经尿道等离子前列腺电切术
经尿道等离子汽化剜切术
良性前列腺增生
Transurethral plasmakinetic resction of prostate
Tansurethral vpor Enucleation rsection of the prostate
Benign prostatic hyperplasia
